Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

A protest was staged at the All India Institute of Medical Sciences or AIIMS, in Delhi on April 26. The AIIMS nurses union began an "indefinite strike" against the suspension of its president Harish Kumar Kajla. The union called the AIIMS administration "undemocratic" and said that Kajla had been suspended without citing proper reasons.
Meanwhile, the AIIMS administration issued a memorandum stating that no employees or faculty members were allowed to stop work for any reason. Nurses were asked to abide by the code of conduct.
Harish Kajla, who was suspended, said that the entire issue was over the safety of women nurses, who were demanding a change in duty hours. He said, "For the last 1, 1.5 years, safety issues were being highlighted over the shifts of women employees. Their duty hours were ending around 9 pm. There's a rise in crime in Delhi late at night. They used to be worried. They suffered eve-teasing etc at bus stops. They raised this issue with the union. The union sent 2-3 written communications to AIIMS admin that duty hours at AIIMS operation theatres and wards end at 8 pm. But in the main OT area, it ends at 9 pm, and women have been facing safety and security issues. Union sought change in duty hours. We had been requesting for 1, 1.5 years, but it wasn't done."

Watch: AIIMS Delhi nurses go on strike, protest against suspension of president; claim women safety issue ignored

((SHORT OPENING VISUALS WITH NAT, TRANSLATION, NO VO))
 ANI REC - 26 APR 2022 - Encoder 1 10-02-36 (2:03 - 2:10) TRANSLATION - We want justice. You want justice. I want justice. You want justice.
&nbsp;
 ((AIIMS NURSE PROTEST VISUALS WITH NAT + VO)) ANI REC - 26 APR 2022 - Encoder 1 10-02-36 Delhi April 26, 2022
 A protest was staged at the All India Institute of Medical Sciences or AIIMS, in Delhi on April 26. The AIIMS nurses union began an "indefinite strike" against the suspension of its president Harish Kumar Kajla. The union called the AIIMS administration "undemocratic" and said that Kajla had been suspended without citing proper reasons.
&nbsp;
 ((AIIMS MEMO SPLIT WITH PROTEST)) https://twitter.com/ANI/status/1518904037416267776
&nbsp;
 Meanwhile, the AIIMS administration issued a memorandum stating that no employees or faculty members were allowed to stop work for any reason. Nurses were asked to abide by the code of conduct. Harish Kajla, who was suspended, said that the entire issue was over the safety of women nurses, who were demanding a change in duty hours.
&nbsp;
 BYTE HARISH KUMAR KAJLA, PRESIDENT, AIIMS NURSES UNION ANI REC - 26 APR 2022 - Encoder 1 10-02-36
(4:07 - 4:58)
 TRANSLATION - For the last 1, 1.5 years, safety issues were being highlighted over the shifts of women employees. Their duty hours were ending around 9 pm. There's a rise in crime in Delhi late at night. They used to be worried. They suffered eve-teasing etc at bus stops. They raised this issue with the union. The union sent 2-3 written communications to AIIMS admin that duty hours at AIIMS operation theatres and wards end at 8 pm. But in the main OT area, it ends at 9 pm, and women have been facing safety and security issues. Union sought change in duty hours. We had been requesting for 1, 1.5 years, but it wasn't done.
===========================================
CAPTIONS Protest at AIIMS Delhi Strike by AIIMS nurses Nurses Union chief suspended Union slammed AIIMS admin 'Women security ignored' Ceasing work not allowed: AIIMS

<div class="elementToProof">The AIIMS&nbsp;Nurses Union began an "indefinite strike" from April 26 against the suspension of its president Harish Kumar Kajla.</div>

A protest was staged at the All India Institute of Medical Sciences or AIIMS, in Delhi on April 26.&nbsp;The AIIMS nurses union began an "indefinite strike" against the suspension of its president Harish Kumar Kajla.&nbsp;The union called the AIIMS administration "undemocratic" and said that Kajla had been suspended without citing proper reasons.
Meanwhile, the AIIMS administration issued a memorandum stating that no employees or faculty members were allowed to stop work for any reason.&nbsp;Nurses were asked to abide by the code of conduct.
Harish Kajla, who was suspended, said that the entire issue was over the safety of women nurses, who were demanding a change in duty hours. He said, "For the last 1, 1.5 years, safety issues were being highlighted over the shifts of women employees. Their duty hours were ending around 9 pm. There's a rise in crime in Delhi late at night. They used to be worried. They suffered eve-teasing etc at bus stops. They raised this issue with the union. The union sent 2-3 written communications to AIIMS admin that duty hours at AIIMS operation theatres and wards end at 8 pm. But in the main OT area, it ends at 9 pm, and women have been facing safety and security issues. Union sought change in duty hours. We had been requesting for 1, 1.5 years, but it wasn't done."

Amid global Omicron concerns, All India Institute of Medical Sciences Director Dr Randeep Guleria sounded alarm on Sunday.
Dr Guleria told news agency ANI that in view of rising Covid-19 cases in the United Kingdom, India should prepare itself for any eventuality.
"We should prepare and hope that things are not as bad as in the United Kingdom. We need more data on Omicron. Whenever there is a surge in cases in other parts of the world, we need to monitor it closely and be prepared for any eventuality. It is better to stay prepared than to get caught off-guard," said Guleria while talking to ANI.
India has so far reported over 150 cases of Omicron variant.
The new variant of Covid-19 was first reported to the World Health Organisation from South Africa on November 25. It has now spread to a number of countries and is likely to beat Delta as the dominant Covid variant.

Omicron alert: India should be prepared for any eventuality, says AIIMS chief Dr Gulerai

AIIMS Director Dr Randeep Guleria has said that in view of rising Covid-19 cases in UK, India should prepare itself for any eventuality

AIIMS chief has sounded alert over Omicron in India

Amid global Omicron concerns, All India Institute of Medical Sciences Director Dr Randeep Guleria sounded alarm on Sunday.
Dr Guleria told news agency ANI that in view of rising Covid-19 cases in the United Kingdom, India should prepare itself for any eventuality.
Byte Dr&nbsp;Randeep&nbsp;Guleria:&nbsp;"We should prepare and hope that things are not as bad as in the United Kingdom. We need more data on Omicron. Whenever there is a surge in cases in other parts of the world, we need to monitor it closely and be prepared for any eventuality. It is better to stay prepared than to get caught off-guard.
India has so far reported over 150 cases of Omicron variant.
The new variant of Covid-19 was first reported to the World Health Organisation from South Africa on November 25. It has now spread to a number of countries and is likely to beat Delta as the dominant Covid variant.

Omicron Scare:&nbsp;India has so far reported over 150 cases of the new&nbsp;variant of Covid-19

Amid global Omicron concerns, All India Institute of Medical Sciences Director Dr Randeep Guleria sounded alarmed on Sunday.
Dr Guleria told news agency ANI that in view of rising Covid-19 cases in the United Kingdom, India should prepare itself for any eventuality.
Also watch |&nbsp;<a href="https://www.editorji.com/india-news/omicron-cases-in-india-cross-150-with-new-patients-in-maharashtra-gujarat-1639967888910" target="_blank">Omicron cases in India cross 150 with new patients in Maharashtra, Gujarat</a>
"We should prepare and hope that things are not as bad as in the United Kingdom. We need more data on Omicron. Whenever there is a surge in cases in other parts of the world, we need to monitor it closely and be prepared for any eventuality. It is better to stay prepared than to get caught off-guard," said Guleria while talking to ANI.
India has so far reported over 150 cases of the Omicron variant.
The new variant of Covid-19 was first reported to the World Health Organisation from South Africa on November 25. It has now spread to a number of countries and is likely to beat Delta as the dominant Covid variant.

Stressing on the need of aggressive containment strategies in the parts of the country that are witnessing a surge in fresh Covid infections, AIIMS Chief Dr Randeep Guleria on Saturday said&nbsp;India's 'R-Value' is inching up, and it's a cause of concern.Dr Guleria&nbsp;told NDTV&nbsp;that starting from .96, and going all the way up to 1, the rise in R-Value is a cause of concern. Simply put, this means that the chances of infection spreading from a person, who has Covid, to others have gone up. He said the&nbsp;areas which are witnessing this surge should bring in restrictions and employ "test, track, and treat" strategy to break the chain of transmission.The AIIMS&nbsp;director's remark come amid fears of a third Covid-19 wave.

AIIMS chief Dr Guleria: India's 'R-Value' surging, cause of concern

AIIMS Chief Dr Randeep Guleria on Saturday said&nbsp;India's 'R-Value' is going up, and it's a cause of concern.

Dr Guleria said the&nbsp;areas which are witnessing this surge should bring in restrictions and employ "test, track, and treat" strategy to break the chain of transmission.

Stressing on the need of aggressive containment strategies in the parts of the country that are witnessing a surge in fresh Covid infections, AIIMS Chief Dr Randeep Guleria on Saturday said&nbsp;India's <a title="In Depth: What is Covid-19 'R' Factor?" href="https://www.edtr.ai/9vpf" target="_blank">'R-Value'</a> is inching up, and it's a cause of concern. Dr Guleria&nbsp;told NDTV&nbsp;that starting from .96, and going all the way up to 1, the rise in R-Value is a cause of concern. Simply put, this means that the chances of infection spreading from a person, who has Covid, to others have gone up. He said the&nbsp;areas which are witnessing this surge should bring in restrictions and employ "test, track, and treat" strategy to break the chain of transmission. The AIIMS&nbsp;director's remark come amid fears of a third Covid-19 wave.

Is India getting fake sense of security from easing covid restriction and optically low numbers? The rising infection levels and a collective look of what's happening around the country raises alarms, here are the top 10 news you need to take note to stay masked and stay safe-:

India's daily fresh case load of covid&nbsp;sees spike, highest number of&nbsp;new cases in 3 weeks being reported
46 districts showing more than 10 per cent positivity rate
53 districts showing positivity&nbsp;rate between five and 10 per cent
Health Ministry: Districts with positivity&nbsp;rate &gt; 10 should consider strict restrictions to prevent/curtail the movement of people
ICMR: States must boost vaccination of 45-60 as fatalities in vulnerable group rising&nbsp;
ICMR: Advised states to avoid all non-essential travel and discourage large gatherings.
Kerala&nbsp;reports over 20,000 fresh cases; 40 per cent of the country's active cases. Raises testing levels to ensure no case goes undetected
Mahrashtra&nbsp;daily count on the rise closes in on 7000, total active cases at 80,871
Epidemiologist&nbsp; Analysis:&nbsp;For Every Single Covid Case in India, 30 Cases Went Missed or Undetected
AIIMS&nbsp;Director Warns:&nbsp;'R-value' is inching up, vaccinations are the only way to come out of pandemic.


India reported 41,831 new cases in 24 hrs: Top 10 headlines you need to pay attention to

Covid numbers down but not out! Top 10 headlines you need to pay attention to.&nbsp;

Covid cases cause concern

India reported 41,831 new cases, 541 deaths in 24 hours
Rising infection levels around the country raises alarms
Highest number of&nbsp;new cases in 3 weeks being reported
Kerala&nbsp;reports over 20,000 fresh cases for more than 5 days
46 districts show more than 10%&nbsp;&nbsp;positivity rate, Centre sends warning message
Centre warns states against crowding as positivity&nbsp;rate rises
'R-value' is inching up,&nbsp;AIIMS&nbsp;Director warns, stresses on vaccination
&nbsp;
&nbsp;

Infection rate across states are starting to see an upswing.&nbsp;

India reported 41,831 new cases, 541 deaths and 39,258 recoveries in the last 24 hours, the Health Ministry data showed on Sunday morning.
Is India getting fake sense of security from easing covid restriction and optically low numbers?
The rising infection levels and a collective look of what's happening around the country raises alarms.
Fresh cases that were declining across Tamil Nadu, Kerala&nbsp;and Karnataka for more than two months have started to rise over the last few days.&nbsp;Complete lockdown&nbsp;has been imposed in Kerala&nbsp;this weekend to curb the spread.
Here are the top 10 news you need to take note to stay masked and stay safe-:
<ol>
<li>India's daily fresh case load of covid&nbsp;sees spike, highest number of&nbsp;new cases in 3 weeks being reported</li>
<li>Kerala&nbsp;reports over 20,000 fresh cases; 40 per cent of the country's active cases. Raises testing levels to ensure no case goes undetected</li>
<li>46 districts showing more than 10 per cent positivity rate</li>
<li>53 districts showing positivity&nbsp;rate between five and 10 per cent</li>
<li>Health Ministry: Districts with positivity&nbsp;rate &gt; 10 should consider strict restrictions to prevent/curtail the movement of people</li>
<li>ICMR: States must boost vaccination of 45-60 as fatalities in vulnerable group rising&nbsp;</li>
<li>ICMR: Advised states to avoid all non-essential travel and discourage large gatherings.</li>
<li>Mahrashtra&nbsp;daily count on the rise closes in on 7000, total active cases at 80,871</li>
<li>Epidemiologist&nbsp; Analysis:&nbsp;For Every Single Covid Case in India, 30 Cases Went Missed or Undetected</li>
<li>AIIMS&nbsp;Director Warns:&nbsp;'R-value' is inching up, vaccinations are the only way to come out of pandemic.</li>
</ol>

According to AIIMS&nbsp;director Dr Guleria, results of the Covaxin&nbsp;trials on children can be expected in September.&nbsp;Trials of Bharat Biotech's Covaxin, India's homegrown&nbsp;vaccine,&nbsp;on children are currently underway, with the second dose of Covaxin&nbsp;likely to be administered to children aged 2-6 years next week. The second dose of Covaxin has already been given to children between the ages of 6-12 years at the Delhi AIIMS.
With good results, Guleria&nbsp;said that the vaccine could be ready for children by September. Trials of Covaxin&nbsp;on children have been going on ever since the DCGI&nbsp;granted permission to Bharat&nbsp;Biotech&nbsp;in May. Trials for Zydus Cadila's vaccine for children are also currently underway in the country.
With the fear of a third Covid-19 wave looming large, some experts have raised concerns that children will be infected in the next wave.

Results of Covaxin trials on children likely by September, AIIMS Director said

In a boost to inoculating India's kids, All India Institute of Medical Sciences (AIIMS) Director Dr Randeep Guleria&nbsp;revealed that results of the Bharat Biotech's Covaxin trials for children are likely to be released by September.

According to AIIMS&nbsp;director Dr Guleria, results of the Covaxin&nbsp;trials on children can be expected in September.&nbsp;
Trials of Bharat Biotech's Covaxin&nbsp;on children are currently underway, with the second dose of the Covid-19 vaccine likely to be administered to children aged 2-6 years next week.
The second dose of Covaxin has already been given to children between the ages of 6-12 years at the Delhi AIIMS.
Trials of Covaxin&nbsp;on children have been going on ever since the DCGI&nbsp;granted permission to Bharat&nbsp;Biotech&nbsp;in May.&nbsp;
With the fear of a third Covid-19 wave looming large, some experts have raised concerns that children will be infected in the next wave.

AIIMS&nbsp;director DR&nbsp;Guleria says trials of Bharat Biotech's Covaxin on children are underway and the results are expected by September.

According to AIIMS&nbsp;director Dr Guleria, results of the Covaxin&nbsp;trials on children can be expected in September.&nbsp;
Trials of Bharat Biotech's Covaxin&nbsp;on children are currently underway, with the second dose of the Covid-19 vaccine likely to be administered to children aged 2-6 years next week.
Also Read&nbsp;<a href="https://www.editorji.com/story/bharat-biotech-terminates-mou-with-brazilian-partners-amid-corruption-allegations-1627062424456" target="_blank">Bharat Biotech terminates MoU with Brazilian partners amid corruption allegations</a>
The second dose of Covaxin has already been given to children between the ages of 6-12 years at the Delhi AIIMS.
Trials of Covaxin&nbsp;on children have been going on ever since the DCGI&nbsp;granted permission to Bharat&nbsp;Biotech&nbsp;in May.&nbsp;
With the fear of a third Covid-19 wave looming large, some experts have raised concerns that children will be infected in the next wave.

The big question o everyone's mind today is when will we have a vaccine against Covid-19 for children. AIIMS Delhi Director Dr Randeep Guleria has now held out hope. Dr Guleria has said that Bharat Biotech and other companies are doing trials at a very fast pace and hoped that a vaccine for children is likely by September-October.
In an interview with ANI, Dr Guleria said that Covaxin's data for children after completion of phase two or three trials is expected by September-October.
Dr Guleria said Bharat Biotech is conducting trials between the age group of 2 to 18 years and "this covers a wide spectrum".
"Children usually have the mild disease but we need to develop vaccines for children because if we have to control this pandemic everyone should be vaccinated," he added.

India may have Covid vaccine for children by September: AIIMS chief Dr Guleria

AIIMS Delhi Director Dr Randeep Guleria has said that Bharat Biotech and other companies are doing trials at a very fast pace and hoped that a vaccine for children is likely by September-October.

India may have Covid vaccine for children by September: AIIMS chief

The big question o everyone's mind today is when will we have a vaccine against Covid-19 for children. AIIMS Delhi Director Dr Randeep Guleria has now held out hope. Dr Guleria has said that Bharat Biotech and other companies are doing trials at a very fast pace and hoped that a vaccine for children is likely by September-October.
In an interview with ANI, Dr Guleria said that Covaxin's data for children after completion of phase two or three trials is expected by September-October.
Dr Guleria said Bharat Biotech is conducting trials between the age group of 2 to 18 years and "this covers a wide spectrum".
"Children usually have the mild disease but we need to develop vaccines for children because if we have to control this pandemic everyone should be vaccinated," he added.

AIIMS director Dr Randeep Guleria has said that Hyderabad based Bharat Biotech&rsquo;s anti-Covid-19 shot, Covaxin, is likely to be approved for children by September.
Dr Guleria told India Today that the trial data would be made available by September and the vaccine itself is likely to be approved in the same month.
He further added that the Pfizer-BioNTech shot, if approved in India, could be another alternative for children to be vaccinated with.
As several experts have projected that a potential third wave will be particularly hard-hitting on children, Covaxin&rsquo;s trial on children, aged between 2 and 17, is being conducted at AIIMS Delhi and Patna

AIIMS chief Dr Guleria: Covaxin likely to be approved for children by September

<ul>
<li>AIIMS chief:&nbsp;Covaxin likely to be approved for children by September</li>
<li>Dr Guleria: Covaxin&nbsp;trial data would be available by September&nbsp;</li>
<li>Pfizer-BioNTech shot another alternative for children,&nbsp;Dr Guleria&nbsp;said</li>
<li>Experts believe a potential third wave will hit children hard</li>
<li>Covaxin&rsquo;s trial on children being conducted at AIIMS Delhi &amp;&nbsp;Patna</li>
</ul>

AIIMS director Dr Randeep Guleria has said that Hyderabad based Bharat Biotech&rsquo;s anti-Covid-19 shot, Covaxin&nbsp;is likely to be approved for children by September.
Dr Guleria told India Today that the trial data would be made available by September and the vaccine itself is likely to be approved in the same month.
He further added that the Pfizer-BioNTech shot, if approved in India, could be another alternative for children to be vaccinated with.
As several experts have projected that a potential third wave will be particularly hard-hitting on children, Covaxin&rsquo;s trial on children, aged between 2 and 17, is being conducted at AIIMS Delhi and Patna

AIIMS Chief Dr Randeep Guleria said that India needs to learn from the UK where the Delta variant is causing a surge in Covid-19 cases.
He said the Delta Plus variant, a mutated version of the more aggressive strain that drove the second wave in India, is undergoing additional mutation which could become a "variant of concern"
Dr Guleria said India could see a faster surge if aggressive Covid-appropriate behaviour is not followed. He also insisted on surveillance to guard against any spike in the Covid cases following unlocking in parts of the country.
He also stressed on the need to ramp up genome sequencing &nbsp;to see if there are more of Delta or Delta plus cases and how the virus is behaving in terms of these two variants.

AIIMS Chief: India can learn from UK where Delta variant is causing surge

//AIIMS&nbsp;chief says be vigilant against Delta variant of Covid-19 //'India needs to learn from UK where the variant is causing a surge' //Dr Guleria:&nbsp;mutated version more aggressive than the strain that caused 2nd wave&nbsp; //'Unlocking should be done with&nbsp;surveillance to guard against any spike cases' //'Need to ramp up genome sequencing to check if there are more Delta or Delta Plus cases'

AIIMS Chief Dr Randeep Guleria said that India needs to learn from the UK where the Delta variant is causing a surge in Covid-19 cases.
He said the Delta Plus variant, a mutated version of the more aggressive strain that drove the second wave in India, is undergoing additional mutation which could become a "variant of concern"
Dr Guleria said India could see a faster surge if aggressive Covid-appropriate behaviour is not followed. He also insisted on surveillance to guard against any spike in the Covid cases following unlocking in parts of the country.
He also stressed on the need to ramp up genome sequencing &nbsp;to see if there are more of Delta or Delta plus cases and how the virus is behaving in terms of these two variants.

All-India Institute of Medical Sciences chief&nbsp;Dr Randeep Guleria&nbsp;has said that a 'mis-classification' of Covid-related deaths by hospitals and state governments can be unhelpful in India's efforts to form strategies to fight the coronavirus pandemic.Dr Guleria&nbsp;told NDTV&nbsp;that for a better picture of mortality in these circumstances, hospitals and state governments must perform a death audit to reconfigure the numbers.&nbsp;
His comments come amid reports and allegations of various state government underplaying the number of deaths.&nbsp;

Covid-related toll audit must for Covid counter strategy: AIIMS chief

All-India Institute of Medical Sciences chief&nbsp;Dr Randeep Guleria&nbsp;has said that a 'mis-classification' of Covid-related deaths by hospitals and state governments can be unhelpful in India's efforts to form strategies to fight the coronavirus pandemic. Dr Guleria&nbsp;told NDTV&nbsp;that for a better picture of mortality in these circumstances, hospitals and state governments must perform a death audit to reconfigure the numbers.&nbsp;
His comments come amid reports and allegations of various state government underplaying the number of deaths.&nbsp;

Covid-related toll audit must for Covid counter strategy: AIIMS chief 

AIIMS&nbsp;chief on 'mis-classification'&nbsp;of Covid-related&nbsp;deaths Guleria: audit necessary to reconfigure Covid toll Guleria's&nbsp;comments amid reports of toll fudging

All-India Institute of Medical Sciences chief&nbsp;Dr Randeep Guleria&nbsp;has said that a 'mis-classification' of Covid-related deaths by hospitals and state governments can be unhelpful in India's efforts to form strategies to fight the coronavirus pandemic. Dr Guleria&nbsp;told NDTV&nbsp;that for a better picture of mortality in these circumstances, hospitals and state governments must perform a death audit to reconfigure the numbers.&nbsp;
His comments come amid reports and allegations of various state government underplaying the number of deaths.&nbsp;

AIIMS Director Dr Randeep Guleria said on Monday that there is no data anywhere in the world to corroborate the fact that the third wave of Covid-19 infections could affect children more than others.He added that according to the second wave data, out of all the children admitted to hospitals with Covid-19, 60-70% had co-morbidities or low immunity, some were on chemo therapy. Guleria said, most healthy children who were infected recovered without the need for hospitalisation.NITI Aayog member Dr VK Paul said, that it would be difficult for the virus to reach children if more and more adults get vaccinated.

60-70% children hospitalised for Covid had co-morbidities: Dr Randeep Guleria

60-70% children hospitalised for Covid&nbsp;during the second wave had co-morbidities, says AIIMS&nbsp;Director&nbsp;Dr Randeep Guleria

AIIMS&nbsp;chief: no data to show that 3rd Covid&nbsp;wave will affect kids
Dr Randeep&nbsp;Guleria: kids hospitalised during 2nd wave had co-morbidities
60-70% kids&nbsp;had co-morbidities,&nbsp;low immunity, were on chemo: Guleria
Most infected children recovered without need for hospitalisation: Guleria
Dr VK Paul: difficult for virus to reach kids if more adults are vaccinated
&nbsp;

AIIMS Director Dr Randeep Guleria said on Monday that there is no data anywhere in the world to corroborate the fact that the third wave of Covid-19 infections could affect children more than others. He added that according to the second wave data, out of all the children admitted to hospitals with Covid-19, 60-70% had co-morbidities or low immunity, some were on chemo therapy. Guleria said, most healthy children who were infected recovered without the need for hospitalisation. NITI Aayog member Dr VK Paul said, that it would be difficult for the virus to reach children if more and more adults get vaccinated.

All India Institute of Medical Sciences Director&nbsp;Dr Randeep&nbsp;Guleria&nbsp;has listed warning signs of Black Fungus in recovering Covid-19 patients.&nbsp;He said if a Covid-19 patient who is recovering can't get rid of that persistent headache or swelling on one side of the face&nbsp;the patient must&nbsp;immediately speak to a doctor and get tested for Black Fungus.&nbsp;&nbsp;&nbsp;Listing other symptoms, the top doctor said Covid-19 patients must also consult doctors&nbsp;if&nbsp;they&nbsp;find&nbsp;discolouration&nbsp;in the mouth and decreased sensation in any part of the face.&nbsp;&nbsp;Listing out more symptoms, Dr&nbsp;Guleria&nbsp;said&nbsp;if the patient&rsquo;s&nbsp;nose is getting blocked and there is thrusting, or&nbsp;if there is loosening of a tooth&nbsp;those are the warning signs of Black Fungus&nbsp;or&nbsp;myucormycosis.&nbsp;An X-ray or a CT scan of the sinuses is done to see if there is infection. A second option, he said, was to do a biopsy through a nasal endoscopy.&nbsp;&nbsp;

AIIMS Director lists Black Fungus warning signs in recovering Covid-19 patients 

All India Institute of Medical Sciences Director&nbsp;Dr Randeep&nbsp;Guleria&nbsp;has listed warning signs of Black Fungus in recovering Covid-19 patients.&nbsp; He said if a Covid-19 patient who is recovering can't get rid of that persistent headache or swelling on one side of the face&nbsp;the patient must&nbsp;immediately speak to a doctor and get tested for Black Fungus.&nbsp;&nbsp; &nbsp; Listing other symptoms, the top doctor said Covid-19 patients must also consult doctors&nbsp;if&nbsp;they&nbsp;find&nbsp;discolouration&nbsp;in the mouth and decreased sensation in any part of the face.&nbsp;&nbsp; Listing out more symptoms, Dr&nbsp;Guleria&nbsp;said&nbsp;if the patient&rsquo;s&nbsp;nose is getting blocked and there is thrusting, or&nbsp;if there is loosening of a tooth&nbsp;those are the warning signs of Black Fungus&nbsp;or&nbsp;myucormycosis.&nbsp; An X-ray or a CT scan of the sinuses is done to see if there is infection. A second option, he said, was to do a biopsy through a nasal endoscopy.&nbsp; &nbsp;

AIIMS Director&nbsp;Dr Randeep&nbsp;Guleria&nbsp;on Black Fungus cases AIIMS Director lists warning signs in Covid-19 patients&nbsp; 'Persistent headache or one-side face swelling: visit a doctor' Dr&nbsp;Guleria:&nbsp;consult doctors&nbsp;if you&nbsp;find&nbsp;discolouration&nbsp;in mouth Top doctor:&nbsp;loosening of tooth warning sign of Black Fungus AIIMS Director: CT scan is needed to see if there is infection

All India Institute of Medical Sciences Director&nbsp;Dr Randeep&nbsp;Guleria&nbsp;has listed warning signs of Black Fungus in recovering Covid-19 patients.&nbsp; He said if a Covid-19 patient who is recovering can't get rid of that persistent headache or swelling on one side of the face&nbsp;the patient must&nbsp;immediately speak to a doctor and get tested for Black Fungus.&nbsp;&nbsp; &nbsp; Listing other symptoms, the top doctor said Covid-19 patients must also consult doctors&nbsp;if&nbsp;they&nbsp;find&nbsp;discolouration&nbsp;in the mouth and decreased sensation in any part of the face.&nbsp;&nbsp; Listing out more symptoms, Dr&nbsp;Guleria&nbsp;said&nbsp;if the patient&rsquo;s&nbsp;nose is getting blocked and there is thrusting, or&nbsp;if there is loosening of a tooth&nbsp;those are the warning signs of Black Fungus&nbsp;or&nbsp;myucormycosis.&nbsp; An X-ray or a CT scan of the sinuses is done to see if there is infection. A second option, he said, was to do a biopsy through a nasal endoscopy.&nbsp; &nbsp;

With an increase in number of Covid-19 positive patients suffering with black fungus,&nbsp;AIIMS&nbsp;Chief Randeep&nbsp;Guleria&nbsp;highlights the cause, symptoms and preventative measures which can be taken to deal with this new emerging problem.

AIIMS chief on Covid & Black Fungus in diabetics 

With an increase in number of Covid-19 positive patients suffering with black fungus,&nbsp;AIIMS&nbsp;Director&nbsp;Randeep&nbsp;Guleria&nbsp;highlighted the cause, symptoms and preventative measures which can be taken to deal with this new emerging problem.

The Indian Radiological and Imaging Association on Wednesday termed&nbsp;AIIMS Director, Dr Randeep Guleria's statements on use of CT scans in evaluation of Covid "misleading".The association said that Guleria's warning that one CT scan is equal to 300-400 x-rays and CT scans cause cancer is "outdated and wrong".
It said the modern CT scanners use ultra low dose CT which has radiation comparable to only 5-10 x-rays.&nbsp;
It said with the advent of low dose CT techniques and advancement in the software, the dose is reduced to one-third to one-fourth and with ultra-low dose CT scan, it can be reduced to one-tenth.

Guleria's CT scan statements 'outdated': Radiological Association 

The Indian Radiological and Imaging Association on Wednesday termed&nbsp;AIIMS Director, Dr Randeep Guleria's statements on use of CT scans in evaluation of Covid "misleading". The association said that Guleria's warning that one CT scan is equal to 300-400 x-rays and CT scans cause cancer is "outdated and wrong".
It said the modern CT scanners use ultra low dose CT which has radiation comparable to only 5-10 x-rays.&nbsp;
It said with the advent of low dose CT techniques and advancement in the software, the dose is reduced to one-third to one-fourth and with ultra-low dose CT scan, it can be reduced to one-tenth.

The Indian Radiological and Imaging Association on Wednesday termed&nbsp;AIIMS Director, Dr Randeep Guleria's statements on use of CT scans in evaluation of Covid "misleading". The association said that Guleria's warning that one CT scan is equal to 300-400 x-rays and CT scans cause cancer is "outdated and wrong".
It said the modern CT scanners use ultra low dose CT which has radiation comparable to only 5-10 x-rays.&nbsp;
It said with the advent of low dose CT techniques and advancement in the software, the dose is reduced to one-third to one-fourth and with ultra-low dose CT scan, it can be reduced to one-tenth.

AIIMS Director Dr Randeep Guleria said on Saturday that India's health infrastructure is &lsquo;stretched to the limit&rsquo; and &lsquo;aggressive lockdowns&rsquo; in areas with positivity rates over 10 per cent are needed to contain the incumbent Covid-19 wave.
Dr Guleria told NDTV that the country had been caught &lsquo;off guard&rsquo; by the ferocity with which the virus was spreading. He said the night curfews and weekend lockdowns - such as those enforced by Uttar Pradesh, Maharashtra, Haryana and other states - were proving to be ineffectual.
He also said the death of a doctor in a Delhi hospital was a personal loss as he had known him since his student days.

Health infra ‘stretched to the limit’, need aggressive lockdowns: AIIMS Director

AIIMS Director Dr Randeep Guleria said on Saturday that India's health infrastructure is &lsquo;stretched to the limit&rsquo; and &lsquo;aggressive lockdowns&rsquo; in areas with positivity rates over 10 per cent are needed to contain the incumbent Covid-19 wave.
Dr Guleria told NDTV that the country had been caught &lsquo;off guard&rsquo; by the ferocity with which the virus was spreading. He said the night curfews and weekend lockdowns - such as those enforced by Uttar Pradesh, Maharashtra, Haryana and other states - were proving to be ineffectual.
He also said the death of a doctor in a Delhi hospital was a personal loss as he had known him since his student days.

AIIMS Director Dr Randeep Guleria has said on the usage of Remdesivir&nbsp;that the medication does not decrease mortality in coronavirus patients. He said the sought-after drug is useful in only hospitalization and it has limited role in moderate illness.
He also said plasma therapy too has limited role.
Guleria said that majority of patients will improve with only with sympathetic treatment and giving drugs when not required will do more harm than good.&nbsp;&nbsp;

Remdesivir useful in only hospitalization: AIIMS Director

Remdivisir useful in only hospitalization: AIIMS Director

//AIIMS&nbsp;director cautions&nbsp;against&nbsp;Remdesivir&nbsp;usage&nbsp; //Drug useful in only hospitalization, for moderate illness: Dr Guleria&nbsp; //'Giving drugs when not required will do more harm than good'

AIIMS Director Dr Randeep Guleria has said on the usage of Remdesivir&nbsp;that the medication does not decrease mortality in coronavirus patients. He said the sought-after drug is useful in only hospitalization and it has limited role in moderate illness.
He also said plasma therapy too has limited role.
Guleria said that majority of patients will improve with only with sympathetic treatment and giving drugs when not required will do more harm than good.&nbsp;&nbsp;

AIIMS Director Dr Randeep Guleria has said that drugmakers AstraZeneca and Bharat Biotech are conducting studies to determine safe and effective doses for children. "If we really need to control the pandemic and have children back to school and be comfortable with that, we will have to look for vaccines which are for children," Dr Guleria told NDTV. AstraZeneca and Bharat Biotech's Covishield and Covaxin vaccines are being used in the country's inoculation drive against the coronavirus. Dr Guleria's remarks came on a day when pharma companies BioNTech-Pfizer declared that their vaccine trials showed 100 per cent efficacy against the coronavirus in children aged between 12 and 15. They are planning to get approval for the vaccine's use in the United States on children under 15.

AstraZeneca, Bharat Biotech testing Covid jabs for children: AIIMS chief

AIIMS Director Dr Randeep Guleria has said that drugmakers AstraZeneca and Bharat Biotech are conducting studies to determine safe and effective doses for children.

AstraZeneca, Bharat Biotech testing Covid jabs for children: AIIMS chief 

AIIMS Director Dr Randeep Guleria has said that drugmakers AstraZeneca and Bharat Biotech are conducting studies to determine safe and effective doses for children. "If we really need to control the pandemic and have children back to school and be comfortable with that, we will have to look for vaccines which are for children," Dr Guleria told NDTV. AstraZeneca and Bharat Biotech's Covishield and Covaxin vaccines are being used in the country's inoculation drive against the coronavirus. Dr Guleria's remarks came on a day when pharma companies BioNTech-Pfizer declared that their vaccine trials showed 100 per cent efficacy against the coronavirus in children aged between 12 and 15. They are planning to get approval for the vaccine's use in the United States on children under 15.

The Covid surge in the country is due to a new strain and the situation is exactly like the one in the UK when the virus underwent a mutation around Christmas, AIIMS chief Dr Randeep Guleria has said.
Speaking to NDTV, Dr Guleria said: "It is likely that there is a variant which is causing the virus to be more infectious and this is part of what we tend to see". The government has so far maintained that there is no evidence that the surge is linked to a mutation of the coronavirus. 
On Tuesday, the government had said that the Covid situation is going from "bad to worse over the last few weeks" and "any complacency at this stage, and at any level, will have heavy costs".

India's Covid surge exactly like UK, new strain likely: AIIMS chief

The Covid surge in India is due to a new strain and the situation is exactly like the one in the UK when the virus underwent a mutation around Christmas:&nbsp;AIIMS chief

The Covid surge in the country is due to a new strain and the situation is exactly like the one in the UK when the virus underwent a mutation around Christmas, AIIMS chief Dr Randeep Guleria has said. Speaking to NDTV, Dr Guleria said: "It is likely that there is a variant which is causing the virus to be more infectious and this is part of what we tend to see". The government has so far maintained that there is no evidence that the surge is linked to a mutation of the coronavirus.

The Covid surge in the country is due to a new strain and the situation is exactly like the one in the UK when the virus underwent a mutation around Christmas, AIIMS chief Dr Randeep Guleria has said.
Speaking to NDTV, Dr Guleria said: "It is likely that there is a variant which is causing the virus to be more infectious and this is part of what we tend to see". The government has so far maintained that there is no evidence that the surge is linked to a mutation of the coronavirus. 
On Tuesday, the government had said that the Covid situation is going from "bad to worse over the last few weeks" and "any complacency at this stage, and at any level, will have heavy costs".

aiims director

Categories